Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and …
Over the last 12 months, insiders at Molecular Templates, Inc. have bought $587,500 and sold $845,833 worth of Molecular Templates, Inc. stock.
On average, over the past 5 years, insiders at Molecular Templates, Inc. have bought $14.28M and sold $7.95M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BIOTECH TARGET N V (10 percent owner) — $2.35M.
The last purchase of 250,000 shares for transaction amount of $587,500 was made by BIOTECH TARGET N V (10 percent owner) on 2024‑04‑02.
2024-11-14 | Sale | 10 percent owner | 1.28M 20.6511% | $0.66 | $845,833 | 0.00% | ||
2024-04-02 | 10 percent owner | 250,000 5.7535% | $2.35 | $587,500 | -26.32% | |||
2023-07-17 | 10 percent owner | 4.26M 6.4706% | $0.47 | $2M | -53.81% | |||
2022-06-16 | See remarks | 30,000 0.0536% | $0.82 | $24,477 | -34.57% | |||
2022-06-13 | 62,000 0.1065% | $0.89 | $55,180 | -42.39% | ||||
2022-06-13 | 62,000 0.1065% | $0.89 | $55,180 | -42.39% | ||||
2022-05-16 | 200,000 0.3584% | $1.18 | $236,200 | -49.57% | ||||
2022-01-06 | 10 percent owner | 200,000 0.3471% | $4.04 | $807,180 | -77.97% | |||
2021-09-21 | 10 percent owner | 750,000 1.2249% | $6.00 | $4.5M | -61.39% | |||
2021-09-16 | 10 percent owner | 100,000 0.176% | $6.13 | $613,000 | -58.39% | |||
2021-07-27 | 10 percent owner | 75,000 0.1333% | $7.09 | $531,840 | -52.96% | |||
2021-07-26 | 10 percent owner | 80,000 0.141% | $7.00 | $559,816 | -52.55% | |||
2021-07-20 | 10 percent owner | 125,000 0.2177% | $7.13 | $891,675 | -52.88% | |||
2021-07-19 | 10 percent owner | 119,382 0.2095% | $6.96 | $830,827 | -51.20% | |||
2021-06-28 | Sale | See remarks | 2,770 0.0049% | $8.36 | $23,157 | -54.01% | ||
2021-04-19 | 10 percent owner | 40,852 0.0709% | $8.08 | $329,941 | -27.38% | |||
2021-04-15 | 10 percent owner | 150,000 0.2646% | $8.62 | $1.29M | -30.65% | |||
2021-04-14 | 10 percent owner | 150,000 0.2714% | $8.37 | $1.26M | -26.73% | |||
2021-04-13 | 10 percent owner | 100,000 0.1769% | $7.81 | $780,970 | -23.00% | |||
2021-04-12 | 10 percent owner | 50,000 0.0914% | $8.02 | $400,830 | -22.31% |
BIOTECH TARGET N V | 10 percent owner | 0 0% | $0.34 | 32 | 1 | <0.0001% |
BB BIOTECH AG | 11192003 169.991% | $0.34 | 1 | 0 | <0.0001% | |
SUTTER HILL VENTURES | 10 percent owner | 4715398 71.6204% | $0.34 | 2 | 2 | |
Hirsch David | 4199035 63.7775% | $0.34 | 2 | 0 | +10.35% | |
BIRD JEFFREY W | director | 3940573 59.8518% | $0.34 | 3 | 3 | +58.99% |
Bellevue Group | $2.31M | 15.64 | 1.03M | 0% | +$0 | 0.04 | |
Bvf Inc Il | $1.17M | 7.93 | 522,238 | -1.84% | -$21,952.00 | 0.01 | |
Silverarc Capital Management Llc | $794,322.00 | 5.39 | 354,608 | 0% | +$0 | 0.01 | |
Adage Capital Partners Gp L L C | $576,130.00 | 3.91 | 257,201 | -12.15% | -$79,661.09 | <0.01 | |
Caxton Corp | $306,580.00 | 2.08 | 136,866 | 0% | +$0 | 1.75 |